

Curriculum Vitae

Name	Kyong Hwa Park, MD, PhD	
Current Position & Affiliation	Professor, Oncology/Hematology, Department of internal medicine, College of medicine, Korea University Adjunctive Professor, Department of medical Education, Korea University College of Medicine Chair, Division of Oncology/Hematology, Department of Internal Medicine, Korea University Anam Hospital Associate Director, Clinical Trial Center, Korea University Anam Hospital	
Country	Korea, Republic of	

Educational Background

2002–2005	Ph. D., Graduate School, Korea University, College of Medicine, Seoul, Korea.
1999–2002:	Graduate School of Korea University, Master’s Course. Majored in Internal Medicine, Seoul, Korea.
1998:	ECFMG Certificate (No. 0-538-258-5).
1990–1998:	MD, College of Medicine, Korea University, Seoul, Korea.

Professional Experience

2018. 3– PRESENT:	Professor, Oncology/Hematology, Department of internal medicine, College of medicine, Korea University
2018. 7 – PRESENT:	Adjunctive Professor, Department of medical Education, Korea University College of Medicine
2016.2 – PRESENT:	Chair, Division of Oncology/Hematology, Department of Internal Medicine, Korea University Anam Hospital
2016.3-Present:	Associate Director, Clinical Trial Center, Korea University Anam Hospital
2014. 3- 2015. 2:	Visiting scientist, Tumor vaccine group in division of Oncology, department of medicine, University of Washington.
2013. 3– 2018. 2:	Associate professor, Korea University

2009. 3– 2013. 2: Assistant professor, Korea University
2007. 9– 2009. 2: Full time lecturer, Oncology/Hematology, Korea University
2007. 6–2007. 8: Clinical Assistant Professor, Oncology/Hematology, Korea University Anam Hospital
2005. 6–2007. 6: Postdoctoral fellow, Tumor vaccine group in division of Oncology, department of medicine, University of Washington.
2004. 3–2005. 5: Clinical fellowship in Division of Oncology/Hematology, Internal Medicine, Korea University Hospital, Seoul, Korea.
1999. 3–2004. 2: Residency in Internal Medicine, Korea University Hospital, Seoul, Korea.
1998. 3–1999. 2: Rotating Internship, Korea University Hospital, Seoul, Korea.

Professional Organizations

Member of Korean Medical Association.
Member of Korean Association of Internal Medicine.
Member of Korean Cancer Study Group.
Member of Korean Cancer Association
Member of American Association of Cancer Research
Member of Society for Immunotherapy of Cancer

Main Scientific Publications

Kang JH, Choi YJ, Seo BY, Jo UH, Park SI, Kim YH, **Park KH**. Scientific Reports volume 9, Article number: 8726 (2019) A Selective FGFR inhibitor AZD4547 suppresses RANKL/M-CSF/OPG-dependent osteoclastogenesis and breast cancer growth in the metastatic bone microenvironment

Kim JW, Choi YJ, Jang WJ, Choi YS, Shin SW, Kim YH, **Park KH**. BMC Palliative Care volume 18, Article number: 84 (2019) Completion rate of physician orders for life-sustaining treatment for patients with metastatic or recurrent cancer: a preliminary, cross-sectional study

Han KC, Park DC, Lee YE, Heo SH, Kim YA, Lee JE, Lee Y, **Park KH**, Park SH, Lee HJ, Lee C, Jang M. Scientific Reports | (2020) 10:5885. Streamlined selection of cancerantigens for vaccine development through integrative multi-omics and high-content cell imaging

Lee S, Lim AR, Kim MJ, Choi YJ, Kim JW, **Park KH**, Shin SW, Kim YH, European Journal of Cancer 136 (2020) 69e7570. Innovative countermeasures can maintain cancer carecontinuity during the coronavirus disease-2019 pandemicin Korea

[Song SE](#), [Cho KR](#), [Seo BK](#), [Woo OH](#), [Park KH](#), [Son YH](#), [Grimm R](#). [J Magn Reson Imaging](#). 2019 Jan;49(1):118-130. Intravoxel incoherent motion diffusion-weighted MRI of invasive breast cancer: Correlation with prognostic factors and kinetic features acquired with computer-aided diagnosis

[Park C](#), [Park H](#), [Lee HJ](#), [Lee HS](#), [Park KH](#), [Choi CH](#), [Na S](#) [Mikrochim Acta](#). 2018 Dec 18;186(1):34. Double amplified colorimetric detection of DNA using gold nanoparticles, enzymes and a catalytic hairpin assembly

[Park IH](#), [Im SA](#), [Jung KH](#), [Sohn JH](#), [Park YH](#), [Lee KS](#), [Sim SH](#), [Park KH](#), [Kim JH](#), [Nam BH](#), [Kim HJ](#), [Kim TY](#), [Lee KH](#), [Kim SB](#), [Ahn JH](#), [Lee S](#), [Ro J](#). [Cancer Res Treat](#). 2019 Jan;51(1):43-52. Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01)

[Choi YJ](#), [Kim HS](#), [Park SH](#), [Kim BS](#), [Kim KH](#), [Lee HJ](#), [Song HS](#), [Shin DY](#), [Lee HY](#), [Kim HG](#), [Lee KH](#), [Lee JL](#), [Park KH](#) [Cancer Res Treat](#). 2018 Oct;50(4):1252-1259. Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05)

[Kim H](#), [Kim CY](#), [Park KH](#), [Kim A](#) [Hum Pathol](#). 2018 Aug;78:106-114 Clonality analysis of multifocal ipsilateral breast carcinomas using X-chromosome inactivation patterns

[Choi JY](#), [Cho EY](#), [Choi YJ](#), [Lee JH](#), [Jung SP](#), [Cho KR](#), [Kim CY](#), [Kim YH](#), [Park KH](#) [Breast Cancer Res Treat](#). 2018 Aug;171(1):181-188 Incidence and risk factors for congestive heart failure in patients with early breast cancer who received anthracycline and/or trastuzumab: a big data analysis of the Korean Health Insurance Review and Assessment service database.

[Choi Y](#), [Yun MS](#), [Lim SH](#), [Lee J](#), [Ahn JH](#), [Kim YJ](#), [Park KH](#), [Park YS](#), [Lim HY](#), [An H](#), [Suh DC](#), [Kim YH](#) [Cancer Res Treat](#). 2018 Jan;50(1):175-182 Gemcitabine and Docetaxel Combination for Advanced Soft Tissue Sarcoma: A Nationwide Retrospective Study

[Park KH](#) et al. [Support Care Cancer](#). 2017 Feb;25(2):505-511. doi: 10.1007/s00520-016-3429-2. A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer.

Norikazu Masuda, M.D, Park KH et al. N Engl J Med 2017; 376:2147-2159
Adjuvant capecitabine for breast cancer after preoperative chemotherapy

Kim HS, Park KH. Et al. Oncology. 2016;91(5):274-282. Incidence and Predictors of Febrile Neutropenia among Early-Stage Breast Cancer Patients Receiving Anthracycline-Based Chemotherapy in Korea.

Park KH, Choi YJ, Kim KW, Ro KH, Kang CH, Song SH, Park JH. Jpn J Clin Oncol. 2016 Sep;46(9):845-9. doi: 10.1093/jjco/hyw081. Combination chemotherapy with methotrexate and vinblastine for surgically unresectable, aggressive fibromatosis.

Seow WJ, Park KH et al. Hum Mol Genet. 2016 Dec 26. pii: ddw414. doi: 10.1093/hmg/ddw414. Association between GWAS-identified lung adenocarcinoma susceptibility loci and EGFR mutations in never-smoking Asian women, and comparison with findings from Western populations.

Kang J, Park JH, Lee HJ, Jo U, Park JK, Seo JH, Kim YH, Kim I, Park KH. Cancer Res Treat. 2016 Apr;48(2):715-26. doi: 10.4143/crt.2015.227. Caveolin-1 Modulates Docetaxel-Induced Cell Death in Breast Cancer Cell Subtypes through Different Mechanisms.

Machiela MJ, Park KH et al. Genetic variants associated with longer telomere length are associated with increased lung cancer risk among never-smoking women in Asia: a report from the female lung cancer consortium in Asia. Int J Cancer. 2015 Jul 15;137(2):311-9. doi: 10.1002/ijc.29393

Kang EJ, Choi YJ, Kim JS, Park KH, Oh SC, Seo JH, Kim HJ, Kang KW, Yu ES, Shin SW, Kim YH, Kim JS. Prognostic Factors for the Selection of Patients Eligible for Second-Line Chemotherapy in Advanced Biliary Tract Cancer. Chemotherapy. 2014;60(2):91-8.

Kim HS, Lee SW, Choi YJ, Shin SW, Kim YH, Cho MS, Lee SN, Park KH. Novel Germline Mutation of BRCA1 Gene in a 56-Year-Old Woman with Breast Cancer, Ovarian Cancer, and Diffuse Large B-Cell Lymphoma. Cancer Res Treat. 2014 Oct 17. doi: 10.4143

Lee SY, Kim HS, Choi YJ, Park KH, Shin SW, Kim YH, Kim ST. A Prognostic Index to Identify Patients With Intrahepatic Cholangiocarcinoma Who Could Benefit From Gemcitabine Plus Cisplatin. *Am J Ther.* 2015 Jan 29

Cecil DL, Holt GE, Park KH, Gad E, Rastetter L, Childs J, Higgins D, Disis ML. Elimination of IL-10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activity. *Cancer Res.* 2014 May 15;74(10):2710-8.

Disis ML, Gad E, Herendeen DR, Lai VP, Park KH, Cecil DL, O'Meara MM, Treuting PM, Lubet RA. A multiantigen vaccine targeting neu, IGFBP-2, and IGF-IR prevents tumor progression in mice with preinvasive breast disease. *Cancer Prev Res (Phila).* 2013 Dec;6(12):1273-82

Gil EY, Jo UH, Lee HJ, Kang J, Seo JH, Lee ES, Kim YH, Kim I, Phan-Lai V, Disis ML, Park KH. Vaccination with ErbB-2 peptides prevents cancer stem cell expansion and suppresses the development of spontaneous tumors in MMTV-PyMT transgenic mice. *Breast Cancer Res Treat.* 2014 Aug;147(1):69-80.

Lee JH, Kang SG, Kim ST, Kang SH, Choi IK, Park YJ, Oh SC, Sung DJ, Seo JH, Cheon J, Shin SW, Kim YH, Kim JS, Park KH. Modified MVAC as a Second-Line Treatment for Patients with Metastatic Urothelial Carcinoma after Failure of Gemcitabine and Cisplatin Treatment. *Cancer Res Treat.* 2014 Apr;46(2):172-7.

Kang EJ, Jung H, Woo OH, Park KH, Woo SU, Yang DS, Kim AR, Lee JB, Kim YH, Kim JS, Seo JH. Association of aldehyde dehydrogenase 1 expression and biologically aggressive features in breast cancer. *Neoplasma.* 2014;61(3):352-62.

Kang EJ, Jung H, Woo OH, Park KH, Woo SU, Yang DS, Kim AR, Lee JB, Kim YH, Kim JS, Seo JH. YKL-40 expression could be a poor prognostic marker in the breast cancer tissue. *Tumour Biol.* 2014 Jan;35(1):277-86.

Cecil DL, Park KH, Gad E, Childs JS, Higgins DM, Plymate SR, Disis ML. T-helper I immunity, specific for the breast cancer antigen insulin-like growth factor-I receptor (IGF-IR), is associated with increased adiposity. *Breast Cancer Res Treat.* 2013 Jun;139(3):657-65.

Kim HS, Sung JS, Yang SJ, Kwon NJ, Jin L, Kim ST, Park KH, Shin SW, Kim HK, Kang JH, Kim JO, Park JY, Choi JE, Yoon H, Park CK, Yang KS, Seo JS, Kim YH. Predictive Efficacy of Low Burden EGFR Mutation Detected by Next-Generation Sequencing on Response to EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Carcinoma. *PLoS One*. 2013 Dec 20;8(12):e81975

Park JH, Lee SW, Kim HS, Kang SG, Ko YH, Kim ST, Kang SH, Park YJ, Choi IK, Oh SC, Sung DJ, Seo JH, Cheon J, Kim YH, Kim JS, **Park KH**. Combination of gemcitabine and carboplatin as first line treatment in elderly patients or those unfit for cisplatin-based chemotherapy with advanced transitional cell carcinoma of the urinary tract. *Cancer Chemother Pharmacol*. 2013 Apr;71(4):1033-9.

Kim ST, Park KH, Kim JS, Shin SW, Kim YH. Impact of KRAS Mutation Status on Outcomes in Metastatic Colon Cancer Patients without Anti-Epidermal Growth Factor Receptor Therapy. *Cancer Res Treat*. 2013 Mar;45(1):55-62.

Wnt5a is associated with cigarette smoke-related lung carcinogenesis via protein kinase C. Whang YM, Jo U, Sung JS, Ju HJ, Kim HK, Park KH, Lee JW, Koh IS, Kim YH. *PLoS One*. 2013;8(1):e53012

Lan Q, Park KH et al. Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. *Nat Genet* 2012 Dec;44(12):1330-5.

Gil EY, Jo UH, Jeong H, Whang YM, Woo OH, Cho KR, Seo JH, Kim A, Lee ES, Koh I, Kim YH, **Park KH**. Promoter methylation of RASSF1A modulates the effect of the microtubule-targeting agent docetaxel in breast cancer. 2012 April, *Int J Oncol*

Park Y, Shin SW, Kim YH, **Park KH**. RASSF1A and ERCC1 Expressions Might Be Predictive of Prognosis in Advanced, Recurrent, and Metastatic Squamous Cell Carcinoma of the Head and Neck Treated with Docetaxel and Cisplatin. *Onkologie* 2012;35(11):673-82

Kim ST, Jeong H, Woo OH, Seo JH, Kim A, Lee ES, Shin SW, Kim YH, Kim JS, **Park KH**. Tumor-infiltrating Lymphocytes, Tumor Characteristics, and Recurrence in Patients With Early Breast Cancer. *Am J Clin Oncol*. 2012 Apr 6

Park KH, Kim JS, Park Y, Seo HY, Park YJ, Choi IK, Oh SC, Seo JH, Kim CY, Jung KY, Shin SW, Kim YH, Kim JS, Lee NJ. Concurrent chemoradiation followed by

adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma in Korea. *Cancer Chemother Pharmacol.* 2010 Sep;66(4):643-51

Park KH, Gad E, Goodell V, Dang Y, Wild T, Higgins D, Fintak P, Childs J, Dela Rosa C, Disis ML. Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer. *Cancer Res.* 2008 Oct 15;68(20):8400-9

Park KH, Han SGL, Whang YM, Lee HJ, Yoo YD, Lee JW, Shin SW, Kim YH. Single nucleotide polymorphisms of the TGFB1 gene and lung cancer risk in a Korean population. *Cancer Genet Cytogenet.* 2006 Aug;169(1):39-44.

Park KH, Rho YH, Choi SJ, Hong SJ, Lee JH, Choi IK, Kim SJ, Seo JH, Choi CW, Kim BS, Shin SW, Kim YH, Song GG, Kim JS. Acute arthritis of carpal bones secondary to metastatic gastric cancer. *Clin Rheumatol.* 2006 Mar;25(2):258-61

Park KH, **Choi IK**, **Kim SJ**, **Oh SC**, **Seo JH**, **Choi CW**, **Kim BS**, **Shin SW**, **Kim YH**, **Kim JS**. The efficacy of epirubicin, cisplatin, uracil/tegafur, and leucovorin in patients with advanced biliary tract carcinoma. *Cancer.* 2005 Jun 1;103(11):2338-43

Kyong Hwa Park, M.D., Byung Soo Kim, M.D., Sook Young Bae, M.D., Soo Young Yoon, M.D., Hye Ryoung Sul, M.D., Jong Gwon Choi, M.D., Hwa Jung Sung, M.D., So Young Yoon, M.D., In Keun Choi, M.D., Sang Cheul Oh, M.D., Jae Hong Seo, M.D., Chul Won Choi, M.D., Sang Won Shin, M.D., Yeul Hong Kim, M.D., and Jun Seok Kim, M.D. Activities of long term stored platelets. *The Korean Journal of Hematology*

Kyong Hwa Park, So Young Yoon, Sang Cheul Oh, Jae Hong Seo, Chul Won Choi, Jong Eun Yeon, Byung Soo kim, Sang Won Shin, Yeul Hong kim, Kwan Soo Byun, Jun Suk Kim and Chang Hong Lee. Pirarubicin, UFT, leucovorin chemotherapy in non-embolizable and transcatheter arterial chemoembolization failed hepatocellular carcinoma patients; a phase II clinical study. *Cancer Research and Treatment* 2002;34:280-283.